Guggenheim Raises Absci Price Target to $15 Amid Bullish Outlook for ABS-201
Guggenheim analysts raised the price target for Absci Corp. (NASDAQ:ABSI) from $10 to $15 on Monday, maintaining a “buy” rating. The new target represents a potential 120% upside from the recent trading price of $6.80. This adjustment follows an internal analysis of the company’s lead asset, ABS-201, which is currently undergoing clinical trials for conditions including endometriosis.
Absci Corp. recorded $215,000 in revenue for the first quarter of 2026, a figure that fell significantly below the anticipated $1.43 million, representing an 84.97% miss on revenue expectations.
Clinical Development and Market Potential
The upward revision by Guggenheim is largely tied to the anticipated release of proof-of-concept data for ABS-201, expected in the second half of 2026. Analysts identify the current market for hair loss treatments as underserved, citing limitations in efficacy and concerns regarding side effects in existing therapies. The ongoing HEADLINE phase 1/2a clinical trial is scheduled to provide 13-week interim data in late 2026, followed by 26-week results in early 2027.
Guggenheim estimates that ABS-201 holds an unadjusted revenue potential of over $5 billion in the United States alone. When including international markets, which the firm expects will be commercialized through partnerships, that figure exceeds $8 billion. While these projections are optimistic, the firm currently assigns a 25% probability of success to the asset as it awaits its first human data readout.
The divergence between Absci’s recent financial performance and the optimism from analysts like Guggenheim and BTIG highlights a classic biotech trade-off. Investors are weighing the immediate, tangible reality of missed revenue targets against the long-term, high-stakes potential of an AI-driven drug discovery platform. The valuation shifts rely heavily on the success of the prolactin portfolio, meaning the clinical timeline for ABS-201 and ABS-202 is now the primary driver of the company’s market narrative.
Financial Outlook and Analyst Sentiment
Absci’s financial profile remains complex. While the company missed revenue expectations in the first quarter of 2026, its earnings per share (EPS) of -$0.19 slightly outperformed the estimated -$0.1943. Beyond Guggenheim, BTIG has also initiated coverage on the company with a “buy” rating and a $9.00 price target, signaling continued institutional interest in the firm’s proprietary AI drug platform.
Guggenheim has adjusted its cost assumptions to reflect a focus on the broader prolactin portfolio, which includes ABS-201 and an undisclosed immunology candidate, ABS-202. These adjustments were incorporated into a discounted cash flow model to arrive at the $15 price target. Despite a 145% return over the past year, investors should note that the stock remains subject to high volatility.
Frequently Asked Questions
What is the primary driver behind the target price increase?
The increase from $10 to $15 is driven by Guggenheim’s analysis of the lead asset ABS-201 and its potential in the hair loss and endometriosis markets, supported by a discounted cash flow model.
When will investors see clinical data for ABS-201?
Interim 13-week proof-of-concept data is expected in the second half of 2026, with 26-week data anticipated in early 2027.
How did Absci perform in the most recent financial quarter?
The company reported $215,000 in revenue, missing expectations of $1.43 million, though it slightly beat EPS estimates with a reported -$0.19 per share.
How do you weigh the risks of clinical-stage biotech volatility against the potential of AI-driven drug discovery platforms?